Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 4—April 2006
Dispatch

MassTag Polymerase Chain Reaction for Differential Diagnosis of Viral Hemorrhagic Fevers

Gustavo Palacios*1, Thomas Briese*1Comments to Author , Vishal Kapoor*, Omar Jabado*, Zhiqiang Liu*, Marietjie Venter†, Junhui Zhai*, Neil Renwick*, Allen Grolla‡, Thomas W. Geisbert§, Christian Drosten¶, Jonathan S. Towner#, Jingyue Ju*, Janusz Paweska**, Stuart T. Nichol#, Robert Swanepoel**, Heinz Feldmann‡††, Peter B. Jahrling‡‡, and W. Ian Lipkin*
Author affiliations: *Columbia University, New York, New York, USA; †University of Pretoria and National Health Laboratory Services, Pretoria, South Africa; ‡Public Health Agency of Canada, Winnipeg, Manitoba, Canada; §United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA; ¶Bernhard-Nocht-Institute of Tropical Medicine, Hamburg, Germany; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **National Institute for Communicable Diseases, Sandringham, South Africa; ††University of Manitoba, Winnipeg, Manitoba, Canada; ‡‡National Institutes of Allergy and Infectious Diseases Integrated Research Facility, Fort Detrick, Frederick, Maryland, USA

Main Article

Table 3

MassTag polymerase chain reaction analysis of clinical specimens from viral hemorrhagic fever patients*

Previous diagnosis Sample identification Sample type Year/origin MassTag result†
ZEBOV 5015 Serum 1995/Kikwit, DRC +++, ZEBOV
ZEBOV 5014 Serum 1995/Kikwit, DRC +++, ZEBOV
ZEBOV 5004 Serum 1995/Kikwit, DRC +++, ZEBOV
ZEBOV 6317 Serum 1995/Kikwit, DRC +++, ZEBOV
ZEBOV 6313 Serum 1995/Kikwit, DRC +++, ZEBOV
MARV 246-00-5 Hemolyzed whole blood 2000/Durba, DRC +, MARV
MARV 226-00-4 Hemolyzed whole blood 2000/Durba, DRC ++, MARV
MARV 246-00-7 Hemolyzed whole blood 2000/Durba, DRC +, MARV
MARV 98-00-2 Hemolyzed whole blood 2000/Durba, DRC +++, MARV
MARV 461 Blood 2005/Uige, Angola +++, MARV
MARV 462 Oral swab 2005/Uige, Angola +++, MARV
MARV 475 Blood 2005/Uige, Angola ++, MARV
MARV 476 Oral swab 2005/Uige, Angola +, MARV
LASV 98-04-1 Serum 2004/Sierra Leone +++, LASV
LASV 98-04 Serum 2004/Sierra Leone ++, LASV
LASV 98-04-5 Serum 2004/Sierra Leone +, LASV
LASV 80-04-1 Serum 2004/Sierra Leone +++, LASV
RVFV 98002009 Serum 1998/Kenya +, RVFV
RVFV H6061989 Serum 1998/Kenya +, RVFV
RVFV 98002019 Serum 1998/Kenya ++, RVFV
RVFV 77-04 Serum 2004/Namibia ++, RVFV
CCHFV 187-86 Serum 1986/South Africa +, CCHFV
CCHFV 30-93 Serum 1993/South Africa +++, CCHFV
CCHFV 465-88 Serum 1988/South Africa +++, CCHFV
CCHFV 407-89 Serum 1989/South Africa +++, CCHFV
CCHFV 215-90 Serum 1990/South Africa ++, CCHFV

*ZEBOV, Ebola Zaire virus; MARV, Marburg virus; LASV, Lassa virus; RVFV, Rift Valley fever virus; CCHV, Crimean-Congo hemorrhagic fever virus; DRC, Democratic Republic of Congo.
†Relative ranking of results: +, signal-to-noise ratio <4; ++, signal-to-noise ratio >4 and <8; +++, signal-to-noise ratio >8.

Main Article

1These authors contributed equally to this article.

Page created: January 24, 2012
Page updated: January 24, 2012
Page reviewed: January 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external